Geovax next-generation covid-19 vaccine data presented at keystone symposia conference

Preclinical data for geo-cm02 demonstrates single-dose protection against multiple sars-cov-2 variants atlanta, ga, sept. 20, 2023 (globe newswire) -- via newmediawire – geovax labs, inc. (nasdaq: govx), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today the presentation of preclinical vaccine efficacy data for geo-cm02, a multi-antigen sars-cov-2 vaccine.
GOVX Ratings Summary
GOVX Quant Ranking